HRP20191513T1 - Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja - Google Patents

Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja Download PDF

Info

Publication number
HRP20191513T1
HRP20191513T1 HRP20191513T HRP20191513T1 HR P20191513 T1 HRP20191513 T1 HR P20191513T1 HR P20191513 T HRP20191513 T HR P20191513T HR P20191513 T1 HRP20191513 T1 HR P20191513T1
Authority
HR
Croatia
Prior art keywords
unsubstituted
substituted
carboaryl
aliphatic
independently selected
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Claude Michel Wischik
Dominic Venay Harbaran
Gernot Riedel
Serena Deiana
Elizabeth Anne Goatman
Damon Jude Wischik
Alison Dorothy Murray
Roger Todd Staff
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of HRP20191513T1 publication Critical patent/HRP20191513T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20191513 2007-06-19 2008-06-17 Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja HRP20191513T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment
EP08762390.6A EP2167095B1 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
HRP20191513T1 true HRP20191513T1 (hr) 2019-11-29

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191513 HRP20191513T1 (hr) 2007-06-19 2008-06-17 Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007231124B2 (en) 2006-03-29 2013-02-21 TauRx Therapeutics Management Ltd 3,7-diamino-10H-phenothiazine salts and their use
EP2205245B1 (en) * 2007-10-03 2015-06-24 WisTa Laboratories Ltd. Therapeutic use of diaminophenothiazines
EP2585073B1 (en) 2010-04-30 2016-04-27 Prosetta Antiviral Inc. Antiviral compounds
AU2011358840B2 (en) * 2011-02-11 2017-05-04 TauRx Therapeutics Management Ltd Phenothiazine diaminium salts and their use
WO2012145567A1 (en) 2011-04-20 2012-10-26 Prosetta Antiviral Inc. Antiviral compounds
EP2951149B1 (en) * 2013-01-30 2018-10-10 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
US10472340B2 (en) * 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
KR20230058533A (ko) * 2016-07-25 2023-05-03 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
DK4364801T3 (da) 2018-07-26 2025-12-22 Taurx Therapeutics Man Ltd Optimeret dosering af diaminophenothiaziner i populationer
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AU2004226876A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
EP3564223A1 (en) * 2004-09-23 2019-11-06 WisTa Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
DK2853293T3 (en) * 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN101460157B (zh) * 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
AU2007231124B2 (en) * 2006-03-29 2013-02-21 TauRx Therapeutics Management Ltd 3,7-diamino-10H-phenothiazine salts and their use
SI2457904T1 (sl) 2006-07-11 2015-02-27 Wista Laboratories Ltd. Postopki sinteze in/ali čiščenje diaminofenotiazinijevih spojin

Also Published As

Publication number Publication date
MY177001A (en) 2020-09-01
WO2008155533A3 (en) 2009-02-19
EP2167095B1 (en) 2019-05-29
CA2690746C (en) 2018-01-02
CN101820884B (zh) 2013-08-28
AU2008265045A1 (en) 2008-12-24
DK2167095T3 (da) 2019-07-29
CA2690746A1 (en) 2008-12-24
SI2167095T1 (sl) 2019-09-30
PT2167095T (pt) 2019-08-06
EP2167095A2 (en) 2010-03-31
JP5725605B2 (ja) 2015-05-27
PL2167095T3 (pl) 2019-11-29
US9211294B2 (en) 2015-12-15
CN101820884A (zh) 2010-09-01
WO2008155533A2 (en) 2008-12-24
US20100184752A1 (en) 2010-07-22
AU2008265045B2 (en) 2014-02-27
HUE045460T2 (hu) 2019-12-30
JP2010530403A (ja) 2010-09-09
BRPI0813670A2 (pt) 2014-12-30
ES2739546T3 (es) 2020-01-31

Similar Documents

Publication Publication Date Title
HRP20191513T1 (hr) Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja
SI2004155T1 (en) Protein aggregation inhibitors
TWI798470B (zh) 作為神經激肽－１受體拮抗劑的化合物及其用途
CN101801942B (zh) 杂环化合物和作为抗癌剂的用途
ES2701089T3 (es) Uso terapéutico de las diaminofenotiazinas
WO2018075993A1 (en) Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
CN103796654B (zh) 氘富集化4-羟基-5-甲氧基-n,1-二甲基-2-氧代-n-[(4-三氟-甲基)苯基]-1,2-二氢喹啉-3-甲酰胺
EP3684772B1 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
ES2632471T3 (es) Novedosa sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
JP2013528600A5 (enExample)
JP2010530403A5 (enExample)
JP2022184965A (ja) ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法
HRP20181027T1 (hr) Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a
WO2003062240A1 (de) Pteridinderivate, verfahren zu deren herstellung und ihre verwendung
JP2014514288A5 (enExample)
JP5733839B2 (ja) 神経変性疾患治療薬
Basavarajaiah et al. Pharmacological Activities of Some 5-Substituted-3-phenyl-Nβ-(substituted-2-oxo-2H-pyrano [2, 3-b] quinoline-3-carbonyl)-1H-indole-2-carboxyhydrazides
ES2847229T3 (es) Compuestos intermedios utilizables en la síntesis de (-)-huperzina y proceso para obtener uno de estos compuestos intermedios
ES3012496T3 (en) Synthesis of a thiosulfonic acid by a step of periodate mediated oxidative coupling of a thiosulfonic acid with an aniline
CN105813643A (zh) 利用含有噻吩并三唑二氮杂*化合物的药物制剂治疗非小细胞肺癌的方法
PE20250745A1 (es) Polimorfos cristalinos de (s)-2-etil-8-metil-1-tia-4,8-diazaspiro[4.5]decan-3-ona como agonista del receptor muscarinico de acetilcolina
WO2016187377A1 (en) Compounds and methods for modulating serotonin receptors in the periphery
WO2017180723A1 (en) Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
PT1272490E (pt) Novo sal de um derivado azo do ácido 5-aminossalicílico
KR20240114743A (ko) 3-(2-브로모-3,4-디하이드록시-페닐)-n-(3,4,5-트리하이드록시-벤질)-티오아크릴아미드의분리된 트랜스 이성질체